New application of novel tetrazine derivatives as potent VEGFR-2 kinase inhibitors and anti-cancer agents

Future Med Chem. 2022 Sep;14(17):1251-1266. doi: 10.4155/fmc-2022-0054. Epub 2022 Aug 11.

Abstract

Background: A novel series of s-tetrazine derivatives was designed as a new scaffold and synthesized efficiently as VEGFR-2 inhibitors for the first time. Methodology & results: The inhibitory activities of the new compounds were tested by MTT assay and enzyme assay, respectively. Western blot assay, cell apoptosis assay and cell migration assay were carried out to study the action mechanism of them. All the synthesized compounds showed evident VEGFR-2 inhibitory activities (IC50 in the range of 88.53-257.55 nM). Compounds 23h, 25d, 26e and 27c showed excellent anti-proliferative activities against the four tested cell lines and were better than sorafenib basically. Conclusion: Compounds with good activities based on this novel scaffold can be screened successfully.

Keywords: VEGFR-2 inhibitors; anti-proliferative; cell migration; enzyme inhibitory; flow cytometry; molecular docking; s-tetrazine; western blotting.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents* / pharmacology
  • Cell Proliferation
  • Dose-Response Relationship, Drug
  • Drug Design
  • Molecular Docking Simulation
  • Molecular Structure
  • Protein Kinase Inhibitors / pharmacology
  • Structure-Activity Relationship
  • Vascular Endothelial Growth Factor Receptor-2*

Substances

  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • Vascular Endothelial Growth Factor Receptor-2